The components of inventory, net as of September 30, 2022 and December 31, 2021 are as follows:

During the nine-month period ended September 30, 2022, we reserved $133,006 of finished goods inventory based on our expectation that this inventory will expire before it can be sold or used in clinical trials. This transaction was recorded in reserve for expiring inventory in the condensed consolidated statements of operations. No such inventory reserves were recorded during the nine-month period ended September 30, 2021.

During the three-month periods ended September 30, 2022 and 2021, we allocated $45,696 and $0, respectively, of finished goods inventory for use in clinical trials. During the nine-month periods ended September 30, 2022 and 2021, we allocated $45,696 and $10,404, respectively, of finished goods inventory for use in clinical trials. These transactions were recorded in research and development expense in the condensed consolidated statements of operations.